Were Analysts Bearish Entellus Medical, Inc. (NASDAQ:ENTL) This Week?

January 10, 2018 - By Adrian Erickson

 Were Analysts Bearish Entellus Medical, Inc. (NASDAQ:ENTL) This Week?

Entellus Medical, Inc. (NASDAQ:ENTL) Ratings Coverage

Among 6 analysts covering Entellus Medical (NASDAQ:ENTL), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Entellus Medical had 9 analyst reports since August 9, 2015 according to SRatingsIntel. The stock of Entellus Medical, Inc. (NASDAQ:ENTL) earned “Buy” rating by Canaccord Genuity on Sunday, August 9. On Thursday, October 6 the stock rating was initiated by Deutsche Bank with “Buy”. Piper Jaffray maintained the shares of ENTL in report on Monday, August 21 with “Buy” rating. The firm has “Hold” rating given on Monday, October 16 by Canaccord Genuity. The stock of Entellus Medical, Inc. (NASDAQ:ENTL) has “” rating given on Tuesday, September 29 by Piper Jaffray. The firm earned “Hold” rating on Friday, December 8 by William Blair. BTIG Research initiated the shares of ENTL in report on Tuesday, June 14 with “Buy” rating. Below is a list of Entellus Medical, Inc. (NASDAQ:ENTL) latest ratings and price target changes.

08/12/2017 Broker: William Blair Rating: Hold Downgrade
16/10/2017 Broker: Canaccord Genuity Rating: Hold New Target: $17.0 Maintain
12/09/2017 Broker: Canaccord Genuity Rating: Hold New Target: $17.0
21/08/2017 Broker: Piper Jaffray Rating: Buy New Target: $21.0 Maintain

The stock decreased 0.33% or $0.08 during the last trading session, reaching $24.2. About 31,463 shares traded. Entellus Medical, Inc. (NASDAQ:ENTL) has declined 17.59% since January 10, 2017 and is downtrending. It has underperformed by 34.29% the S&P500.

Entellus Medical, Inc., a medical technology company, focuses on the design, development, and commercialization of products for the minimally invasive treatment of patients suffering from chronic and recurrent sinusitis. The company has market cap of $616.59 million. The firm offers XprESS Multi-Sinus Dilation family of products consisting of XprESS Pro device, XprESS LoProfile device, and XprESS Ultra device, which open an obstructed or narrowed drainage pathway of a sinus cavity by means of trans-nasal balloon sinus dilation. It currently has negative earnings. It also provides PathAssist tools, such as LED Light Fiber, a single-use tool that provides real-time high intensity red trans-illumination of the sinus cavity with its battery power; Light Fiber, a single-use tool that provides real-time trans-illumination of the sinus cavity; Light Seeker, a tool with optical fibers embedded into the device to allow ear, nose, and throat physicians to access the frontal sinus and trans-illuminate the sinus cavity; Maxillary Seeker, a tool that allow users to find the correct angle to access the natural maxillary ostia; and Sphenoid Seeker/Freer, a two-in-one tool that enables ENT physicians to navigate access to the sphenoid ostium.

More notable recent Entellus Medical, Inc. (NASDAQ:ENTL) news were published by: Globenewswire.com which released: “Entellus Medical Announces New Employee Inducement Option Grants” on August 08, 2017, also Prnewswire.com with their article: “ACT NOW: Monteverde & Associates PC Announces An Investigation Of Entellus …” published on January 08, 2018, Globenewswire.com published: “Entellus Medical to Participate in Upcoming Investor Conferences” on November 14, 2017. More interesting news about Entellus Medical, Inc. (NASDAQ:ENTL) were released by: Globenewswire.com and their article: “Entellus Medical Announces Definitive Agreement to Acquire Spirox” published on July 07, 2017 as well as Fool.com‘s news article titled: “Here’s Why Entellus Medical Inc. Stock Is Under the Weather Today” with publication date: May 04, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.